Latest news

Collaboration with Imperial College to evaluate EYP001

ENYO Pharma is pleased to announce the initiation of a research collaboration with Professor Julian Walters at Imperial College London. The main goal of these investigations is to evaluate the potential for therapeutic use of the FXR agonist EYP001. Explants of human ileum from healthy subjects will be exposed to increasing concentrations of ENYO Pharma’s FXR agonist.

Read more »

ENYO Pharma joins The Liver Forum

ENYO Pharma is pleased to join The Liver Forum at the Forum for Collaborative Research, “to advance the regulatory sciences for the treatment of NASH and liver fibrosis, which is emerging as a leading cause of advanced liver disease in the U.S. and worldwide” (http://www.forumresearch.org/projects/liver-forum). The Liver Forum provides an independent and neutral venue for ongoing multi-stakeholder dialogue. This project will allow our biotech to participate in fruitful meetings and discussions focused on advancing the regulatory sciences for the treatment of NASH and liver fibrosis.

Read more »

Charles River Laboratories and ENYO Pharma today announced results of a successful collaboration

(http://ir.criver.com/phoenix.zhtml?c=121668&p=irol-newsArticle&ID=2318801)

Read more »

Initiation of a collaboration with Paris-Diderot University to discover new drugs against adenoviruses

ENYO Pharma announces its collaboration with Paris-Diderot University, Inserm Unit U941 (Institut Universitaire d’Hématologie), leaded by IDF Innov SATT, to discover new drugs against adenoviruses. The collaboration, built upon ENYO Pharma’s unique approach inspired by viruses, will identify new human cellular targets and pathway essential for replication of adenoviruses. This information will help to select experimental or clinical-stage small molecules that will be tested in a drug repositioning strategy. ENYO pharma will provide its peptide and small molecule libraries to the University team which will screen and analyse their impact on adenoviruses’

Read more »

ENYO Pharma pursues its international strategy and opens a new subsidiary in Australia

ENYO Pharma has opened its first wholly owned subsidiary in Australia. This office will be our new center to manage clinical trials in the Asia-Pacific region. ENYO Pharma has based its innovation on mimicking virus strategies to discover new cellular targets and develop drug candidates in infectious diseases and beyond.

Read more »